At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,201 enrolled
Drug / intervention
semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating semaglutide and Dulaglutide for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 1,201 participants across 209 sites in 17 countries.
Detailed Summary
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesBulgaria, Croatia, Finland, Germany, Greece, Hong Kong, India, Ireland, Latvia, Lithuania, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartJan 2016
Primary CompletionApr 2017
Study CompletionMay 2017
TodayJul 2026
First PostedJan 6, 2016
Enrollment StartJan 6, 2016
Primary CompletionApr 10, 2017
Study CompletionMay 19, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.5 years ago
Interventions
semaglutidedrug
Administered subcutaneously (s.c., under the skin) once-weekly.
Dulaglutidedrug
Administered subcutaneously (s.c., under the skin) once-weekly.